Current guidelines recommend combination antiretroviral treatment for all patients with HIV
infection. 1, 2 The backbone of this treatment regimen is a dual nucleoside reverse …

Once-daily single-tablet regimens represent the paramount simplification of antiretroviral
treatment achieved so far. They include drugs with favorable pharmacokinetics that allow …

Objective: To review the pharmacokinetics, safety, drug-drug interactions, and advantages
and disadvantages of currently available single-tablet regimens (STRs) for HIV-1 infection …

Abstract Background Multi-tablet regimens (MTRs) are associated with increased adverse
events and non-adherence. Single tablet regimens (STRs) plus boosted protease inhibitors …

Existing guidelines for the treatment of HIV infection recommend the use of a dual
nucleoside reversetranscriptase inhibitor backbone with a non-nucleoside reverse …

Early versions of highly-active antiretroviral therapy (HAART) characteristically involved
complicated combinations of different drugs, which were taken as varying numbers of pills …

Background Dosing frequency is an important determinant of regimen effectiveness.
Methods To compare efficacy of once-daily (QD) versus twice-daily (BID) antiretroviral …

Newer HIV regimens are typically taken once daily but vary in the number of pills required.
Whether the number of pills in a once-daily HIV regimen affects clinical outcomes is …

Objectives To compare outcomes with single tablet regimens (STR) versus multi-tablet
regimens (MTR) for human immunodeficiency virus (HIV) treatment using published data …

Objectives: Review of the available data on the currently available single-tablet regimens
(STRs), from the analysis of efficacy and safety to the key points of value in terms of …